These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31334834)

  • 1. Depletion of regulatory FoxP3
    Amakata M; Teraki Y
    Int J Dermatol; 2019 Dec; 58(12):e247-e249. PubMed ID: 31334834
    [No Abstract]   [Full Text] [Related]  

  • 2. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.
    Ishida T; Ito A; Sato F; Kusumoto S; Iida S; Inagaki H; Morita A; Akinaga S; Ueda R
    Cancer Sci; 2013 May; 104(5):647-50. PubMed ID: 23360455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
    Honda T; Hishizawa M; Kataoka TR; Ohmori K; Takaori-Kondo A; Miyachi Y; Kabashima K
    Acta Derm Venereol; 2015 May; 95(5):606-7. PubMed ID: 25424342
    [No Abstract]   [Full Text] [Related]  

  • 4. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
    Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
    Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
    [No Abstract]   [Full Text] [Related]  

  • 5. CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma.
    Ito A; Sugita K; Adachi K; Hosoda Y; Motokura T; Yamamoto O
    Acta Derm Venereol; 2017 Mar; 97(3):377-378. PubMed ID: 27786349
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab.
    Tanba K; Uoshima N; Uchiyama H; Kawata E; Isa R; Yamaguchi J; Tsutsumi Y; Akaogi T; Kobayashi Y; Katsura K; Kuroda J; Taniwaki M
    Ann Hematol; 2016 Mar; 95(4):661-2. PubMed ID: 26754634
    [No Abstract]   [Full Text] [Related]  

  • 7. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
    Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
    Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
    Kanno K; Honma M; Ishida-Yamamoto A
    J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
    [No Abstract]   [Full Text] [Related]  

  • 10. Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.
    Morishige S; Nishi M; Saruta H; Arakawa F; Yamasaki Y; Oya S; Nakamura T; Seki R; Yamaguchi M; Aoyama K; Mouri F; Osaki K; Ohshima K; Nagafuji K
    Int J Hematol; 2019 Oct; 110(4):506-511. PubMed ID: 31152415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mogamulizumab-induced toxicoderma-like eruptions and autoimmune hepatitis successfully treated with azathioprine in adult T-cell leukaemia/lymphoma.
    Nishizawa A; Ishikawa T; Hirose M; Satoh H; Nishii S; Tomita K; Hokari R; Satoh T
    Eur J Dermatol; 2017 Dec; 27(6):651-652. PubMed ID: 28739547
    [No Abstract]   [Full Text] [Related]  

  • 12. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
    Iida S; Ishida T; Ueda R
    Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor.
    Horii M; Kobayashi T; Maeda S; Takehara K; Matsushita T
    J Dermatol; 2019 Nov; 46(11):e434-e436. PubMed ID: 31342541
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study.
    Maemoto H; Ariga T; Kusada T; Heianna J; Manabe Y; Miyakawa A; Nakachi S; Morishima S; Iraha S; Ganaha F; Masuzaki H; Murayama S
    Jpn J Clin Oncol; 2019 Feb; 49(2):153-159. PubMed ID: 30452692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib.
    Nühnen VP; Schön MP; Mössner R
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):199-201. PubMed ID: 29328518
    [No Abstract]   [Full Text] [Related]  

  • 16. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Eginli A; Shah K; Watkins C; Krishnaswamy G
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):143-147. PubMed ID: 28153080
    [No Abstract]   [Full Text] [Related]  

  • 17. Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
    Shima T; Kamezaki K; Higashioka K; Takashima S; Yoshimoto G; Kato K; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Akashi K
    Intern Med; 2016; 55(13):1793-6. PubMed ID: 27374686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.
    Sekiguchi Y; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Kinoshita A; Suga Y; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2014; 7(9):6278-90. PubMed ID: 25337281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies.
    Ohyama Y; Kumode T; Eguchi G; Yamaguchi T; Maeda Y
    Ann Hematol; 2014 Jan; 93(1):169-71. PubMed ID: 23612772
    [No Abstract]   [Full Text] [Related]  

  • 20. CD8+ T cell-mediated interface dermatitis during combination chemotherapy with mogamulizumab in a patient with adult T-cell leukaemia/lymphoma.
    Tani N; Sugita K; Ito A; Ooi S; Yamamoto O
    Clin Exp Dermatol; 2018 Aug; 43(6):736-737. PubMed ID: 29744911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.